| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostate | 25 | 2023 | 122 | 6.700 |
Why?
|
| Lower Urinary Tract Symptoms | 12 | 2022 | 20 | 4.170 |
Why?
|
| Prostatic Hyperplasia | 13 | 2023 | 35 | 3.130 |
Why?
|
| Prostatic Neoplasms | 24 | 2024 | 492 | 3.120 |
Why?
|
| Receptors, CXCR4 | 5 | 2019 | 43 | 2.200 |
Why?
|
| Chemokine CXCL12 | 8 | 2019 | 27 | 2.060 |
Why?
|
| Receptors, Androgen | 14 | 2025 | 86 | 1.760 |
Why?
|
| Fibrosis | 10 | 2023 | 171 | 1.590 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 9 | 2025 | 46 | 1.500 |
Why?
|
| Myofibroblasts | 5 | 2018 | 21 | 1.230 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 522 | 1.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2025 | 583 | 1.090 |
Why?
|
| 5-alpha Reductase Inhibitors | 4 | 2019 | 11 | 1.080 |
Why?
|
| Chemokines, CXC | 4 | 2022 | 33 | 1.070 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2019 | 5 | 1.020 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 309 | 1.020 |
Why?
|
| Male | 56 | 2025 | 30809 | 0.860 |
Why?
|
| Sitosterols | 1 | 2023 | 3 | 0.820 |
Why?
|
| Phytosterols | 1 | 2023 | 8 | 0.820 |
Why?
|
| Cell Line, Tumor | 20 | 2025 | 1558 | 0.780 |
Why?
|
| Cell Proliferation | 11 | 2019 | 1031 | 0.770 |
Why?
|
| Diet, High-Fat | 3 | 2019 | 180 | 0.750 |
Why?
|
| Collagen | 6 | 2023 | 134 | 0.740 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2006 | 33 | 0.720 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2010 | 204 | 0.710 |
Why?
|
| Urinary Tract Physiological Phenomena | 4 | 2020 | 4 | 0.620 |
Why?
|
| Transcription, Genetic | 10 | 2024 | 907 | 0.600 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 197 | 0.600 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 176 | 0.590 |
Why?
|
| Transforming Growth Factor beta | 5 | 2022 | 182 | 0.590 |
Why?
|
| Chemokine CXCL5 | 2 | 2008 | 9 | 0.550 |
Why?
|
| Humans | 56 | 2025 | 64773 | 0.550 |
Why?
|
| Androgen Antagonists | 2 | 2017 | 32 | 0.540 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 92 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 165 | 0.520 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 181 | 0.510 |
Why?
|
| Epithelial Cells | 5 | 2019 | 417 | 0.490 |
Why?
|
| Histone Demethylases | 5 | 2024 | 28 | 0.490 |
Why?
|
| Stilbenes | 1 | 2016 | 22 | 0.490 |
Why?
|
| Androgens | 4 | 2020 | 66 | 0.480 |
Why?
|
| Prostate-Specific Antigen | 5 | 2012 | 84 | 0.470 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 1220 | 0.450 |
Why?
|
| Fibroblasts | 3 | 2023 | 414 | 0.440 |
Why?
|
| Testosterone | 4 | 2025 | 128 | 0.440 |
Why?
|
| Retinoblastoma Protein | 4 | 2025 | 45 | 0.440 |
Why?
|
| Transcriptome | 1 | 2018 | 396 | 0.430 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2014 | 2 | 0.420 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 4 | 2024 | 21 | 0.420 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 9 | 0.420 |
Why?
|
| Antidiuretic Agents | 1 | 2013 | 3 | 0.410 |
Why?
|
| Biomarkers | 4 | 2016 | 1467 | 0.400 |
Why?
|
| Chemokine CCL11 | 1 | 2012 | 4 | 0.380 |
Why?
|
| Mice | 18 | 2025 | 11100 | 0.380 |
Why?
|
| Plant Extracts | 1 | 2013 | 129 | 0.370 |
Why?
|
| Chemokines | 2 | 2011 | 93 | 0.350 |
Why?
|
| Repressor Proteins | 1 | 2014 | 350 | 0.350 |
Why?
|
| Signal Transduction | 11 | 2025 | 3148 | 0.350 |
Why?
|
| Prostatitis | 1 | 2011 | 2 | 0.350 |
Why?
|
| Animals | 22 | 2025 | 21309 | 0.320 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 108 | 0.300 |
Why?
|
| Obesity | 2 | 2019 | 1263 | 0.300 |
Why?
|
| Gossypol | 1 | 2008 | 1 | 0.290 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2008 | 298 | 0.290 |
Why?
|
| Apoptosis | 2 | 2016 | 1094 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 728 | 0.280 |
Why?
|
| Urology | 1 | 2008 | 46 | 0.260 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 2277 | 0.260 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2017 | 9 | 0.260 |
Why?
|
| Middle Aged | 8 | 2023 | 18115 | 0.260 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 563 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 439 | 0.250 |
Why?
|
| Codon, Nonsense | 2 | 2017 | 61 | 0.250 |
Why?
|
| Urinary Bladder | 3 | 2025 | 48 | 0.240 |
Why?
|
| Cadherins | 1 | 2006 | 90 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2019 | 64 | 0.240 |
Why?
|
| Urethra | 2 | 2020 | 78 | 0.240 |
Why?
|
| Down-Regulation | 2 | 2004 | 325 | 0.230 |
Why?
|
| Inosine | 1 | 2025 | 5 | 0.230 |
Why?
|
| Chromosome Deletion | 2 | 2004 | 42 | 0.230 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2025 | 8 | 0.230 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 1007 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2008 | 270 | 0.220 |
Why?
|
| Cellular Senescence | 1 | 2005 | 120 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 733 | 0.220 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 44 | 0.220 |
Why?
|
| Biopsy | 2 | 2019 | 454 | 0.220 |
Why?
|
| Spinal Cord Injuries | 1 | 2025 | 54 | 0.220 |
Why?
|
| Urodynamics | 3 | 2019 | 15 | 0.210 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2024 | 8 | 0.210 |
Why?
|
| Aged | 9 | 2023 | 14843 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 605 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2022 | 78 | 0.210 |
Why?
|
| Transcription Factor AP-1 | 1 | 2024 | 46 | 0.210 |
Why?
|
| Disease Progression | 4 | 2025 | 1210 | 0.210 |
Why?
|
| Genes, Neoplasm | 1 | 2003 | 25 | 0.200 |
Why?
|
| Histones | 2 | 2023 | 493 | 0.200 |
Why?
|
| DNA Damage | 1 | 2025 | 292 | 0.190 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2022 | 4 | 0.190 |
Why?
|
| Cell Lineage | 1 | 2024 | 282 | 0.190 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1633 | 0.190 |
Why?
|
| Finasteride | 2 | 2019 | 7 | 0.190 |
Why?
|
| Interleukin-13 | 1 | 2022 | 37 | 0.190 |
Why?
|
| Interleukins | 1 | 2022 | 86 | 0.190 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2016 | 30 | 0.180 |
Why?
|
| Interleukin-4 | 1 | 2022 | 147 | 0.180 |
Why?
|
| Gene Amplification | 2 | 2021 | 27 | 0.180 |
Why?
|
| Chromatin | 6 | 2024 | 640 | 0.180 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 9 | 0.180 |
Why?
|
| Urination | 2 | 2019 | 16 | 0.180 |
Why?
|
| E2F1 Transcription Factor | 1 | 2022 | 18 | 0.180 |
Why?
|
| Biotechnology | 1 | 2002 | 37 | 0.180 |
Why?
|
| RNA, Messenger | 5 | 2021 | 1572 | 0.180 |
Why?
|
| Computational Biology | 2 | 2019 | 364 | 0.170 |
Why?
|
| Aging | 4 | 2019 | 761 | 0.170 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 37 | 0.170 |
Why?
|
| Protein Binding | 3 | 2020 | 1640 | 0.170 |
Why?
|
| Gene Dosage | 1 | 2021 | 70 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 792 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 72 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 227 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2008 | 810 | 0.160 |
Why?
|
| Urinary Tract | 1 | 2019 | 10 | 0.150 |
Why?
|
| Doxazosin | 1 | 2019 | 1 | 0.150 |
Why?
|
| Organogenesis | 1 | 2019 | 40 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 178 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 80 | 0.150 |
Why?
|
| Cyclic GMP | 1 | 2019 | 33 | 0.150 |
Why?
|
| Fibroins | 1 | 2018 | 5 | 0.150 |
Why?
|
| Urinary Bladder Diseases | 1 | 2018 | 10 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 312 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 160 | 0.140 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 1285 | 0.140 |
Why?
|
| Procollagen | 1 | 2018 | 11 | 0.140 |
Why?
|
| COP-Coated Vesicles | 1 | 2018 | 3 | 0.140 |
Why?
|
| Cullin Proteins | 1 | 2018 | 10 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2019 | 122 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 461 | 0.140 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2008 | 17 | 0.140 |
Why?
|
| Mice, SCID | 4 | 2025 | 518 | 0.140 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 90 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2018 | 117 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 989 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 146 | 0.130 |
Why?
|
| Regeneration | 1 | 2018 | 121 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 206 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 297 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 115 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2017 | 5 | 0.130 |
Why?
|
| Ketoconazole | 1 | 2017 | 11 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2019 | 489 | 0.130 |
Why?
|
| Cell Movement | 2 | 2010 | 476 | 0.130 |
Why?
|
| Metabolome | 1 | 2016 | 36 | 0.120 |
Why?
|
| Liver | 1 | 2021 | 867 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2008 | 205 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2016 | 127 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 217 | 0.110 |
Why?
|
| Chromosome Mapping | 3 | 2006 | 295 | 0.110 |
Why?
|
| Alleles | 3 | 2006 | 452 | 0.110 |
Why?
|
| Software | 1 | 2018 | 393 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 235 | 0.110 |
Why?
|
| Time Factors | 2 | 2019 | 3753 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 851 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2008 | 508 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 6 | 0.100 |
Why?
|
| Female | 8 | 2025 | 33762 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2023 | 37 | 0.100 |
Why?
|
| RNA Interference | 2 | 2019 | 643 | 0.100 |
Why?
|
| Lysine | 2 | 2023 | 94 | 0.100 |
Why?
|
| Diet, Fat-Restricted | 1 | 2013 | 34 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 129 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 461 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2019 | 2603 | 0.100 |
Why?
|
| Chemokine CCL1 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Glucose Tolerance Test | 1 | 2013 | 98 | 0.100 |
Why?
|
| Cellular Microenvironment | 1 | 2012 | 22 | 0.100 |
Why?
|
| Kallikreins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 71 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 94 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 147 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 3468 | 0.090 |
Why?
|
| Butadienes | 1 | 2012 | 14 | 0.090 |
Why?
|
| Dietary Fats | 1 | 2013 | 178 | 0.090 |
Why?
|
| Antibodies | 1 | 2012 | 187 | 0.090 |
Why?
|
| Orchiectomy | 3 | 2020 | 40 | 0.090 |
Why?
|
| Androstadienes | 1 | 2012 | 43 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 84 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2024 | 84 | 0.090 |
Why?
|
| Neoplasms | 1 | 2002 | 1357 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 15 | 0.090 |
Why?
|
| Hormones | 1 | 2011 | 62 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5764 | 0.080 |
Why?
|
| Ligands | 1 | 2012 | 416 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2008 | 610 | 0.080 |
Why?
|
| Nanostructures | 1 | 2012 | 187 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 980 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 5565 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 97 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2010 | 78 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1104 | 0.080 |
Why?
|
| Risk Factors | 2 | 2012 | 5399 | 0.080 |
Why?
|
| Cytokines | 2 | 2011 | 953 | 0.080 |
Why?
|
| DNA Replication | 2 | 2025 | 247 | 0.070 |
Why?
|
| Insulin | 1 | 2013 | 692 | 0.070 |
Why?
|
| Prognosis | 1 | 2014 | 1773 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 687 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2003 | 168 | 0.070 |
Why?
|
| Genes, bcl-2 | 1 | 2008 | 10 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6811 | 0.070 |
Why?
|
| Carboplatin | 1 | 2008 | 46 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2003 | 287 | 0.070 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 240 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2008 | 45 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 41 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 426 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 44 | 0.070 |
Why?
|
| Tissue Banks | 1 | 2008 | 6 | 0.070 |
Why?
|
| Serum | 1 | 2008 | 27 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 94 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 38 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 554 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2008 | 102 | 0.070 |
Why?
|
| Plasma | 1 | 2008 | 38 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2007 | 16 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 512 | 0.060 |
Why?
|
| Transfection | 2 | 2021 | 700 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 152 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 285 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1382 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 213 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2024 | 221 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 43 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 507 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2008 | 579 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 240 | 0.060 |
Why?
|
| Mitochondrial Dynamics | 1 | 2025 | 10 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2025 | 75 | 0.060 |
Why?
|
| Karyotyping | 1 | 2004 | 48 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2003 | 870 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2025 | 78 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 202 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2008 | 1002 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 74 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2024 | 34 | 0.050 |
Why?
|
| SOX9 Transcription Factor | 1 | 2024 | 13 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 1187 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2024 | 41 | 0.050 |
Why?
|
| Cell Plasticity | 1 | 2024 | 24 | 0.050 |
Why?
|
| Neoplastic Processes | 1 | 2023 | 3 | 0.050 |
Why?
|
| Demethylation | 1 | 2023 | 4 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2005 | 435 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 623 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 202 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 119 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2023 | 1550 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2003 | 12 | 0.050 |
Why?
|
| beta-Defensins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 107 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 640 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2024 | 138 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2025 | 317 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2005 | 960 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2023 | 67 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 120 | 0.050 |
Why?
|
| Proteomics | 1 | 2025 | 291 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2188 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 260 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2002 | 11 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 112 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 405 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 856 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2003 | 311 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 18 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2002 | 45 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 1580 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 114 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 1996 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 174 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2020 | 8 | 0.040 |
Why?
|
| Phenotype | 1 | 2004 | 1231 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 403 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 286 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 36 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 98 | 0.040 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2019 | 7 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 173 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 78 | 0.040 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2019 | 4 | 0.040 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2019 | 9 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 339 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2019 | 251 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2021 | 391 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 793 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 301 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2019 | 164 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 1214 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2019 | 211 | 0.030 |
Why?
|
| Goals | 1 | 2018 | 95 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 395 | 0.030 |
Why?
|
| Zebrafish | 1 | 2021 | 369 | 0.030 |
Why?
|
| Dutasteride | 1 | 2017 | 4 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2017 | 12 | 0.030 |
Why?
|
| COS Cells | 1 | 2017 | 180 | 0.030 |
Why?
|
| Quality Control | 1 | 2016 | 78 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 52 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 149 | 0.030 |
Why?
|
| Metabolomics | 1 | 2016 | 59 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 221 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 292 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2016 | 91 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 148 | 0.030 |
Why?
|
| United States | 1 | 2008 | 8051 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 1033 | 0.030 |
Why?
|
| Machine Learning | 1 | 2016 | 192 | 0.030 |
Why?
|
| DNA Primers | 2 | 2006 | 300 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 543 | 0.020 |
Why?
|
| DNA, Neoplasm | 2 | 2003 | 60 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2004 | 165 | 0.020 |
Why?
|
| RNA, Neoplasm | 2 | 2003 | 36 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 65 | 0.020 |
Why?
|
| Materials Testing | 1 | 2012 | 87 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 284 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2011 | 16 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 55 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 542 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 428 | 0.020 |
Why?
|
| Peptide Library | 1 | 2008 | 33 | 0.020 |
Why?
|
| Prostatism | 1 | 2007 | 1 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2007 | 9 | 0.020 |
Why?
|
| Michigan | 1 | 2007 | 44 | 0.020 |
Why?
|
| Minnesota | 1 | 2007 | 45 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 244 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.020 |
Why?
|
| Social Class | 1 | 2007 | 138 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 666 | 0.020 |
Why?
|
| Community Health Services | 1 | 2007 | 124 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2006 | 21 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 52 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 670 | 0.010 |
Why?
|
| Genome, Human | 1 | 2008 | 237 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2036 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 9 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2004 | 56 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2004 | 129 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 61 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 70 | 0.010 |
Why?
|
| Micromanipulation | 1 | 2003 | 4 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 25 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 37 | 0.010 |
Why?
|
| Dissection | 1 | 2003 | 46 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 24 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 152 | 0.010 |
Why?
|
| Multigene Family | 1 | 2002 | 106 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 448 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2002 | 140 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 364 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 161 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 413 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 677 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1592 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1984 | 0.010 |
Why?
|
| Adult | 1 | 2007 | 17239 | 0.010 |
Why?
|